The ASL Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 human cell line, engineered to disrupt the ASL gene. This product consists of a heterogeneous pool of edited cells collectively lacking functional argininosuccinate lyase, providing a versatile loss-of-function model without monoclonal isolation. The polyclonal format preserves population-level diversity while ensuring target-gene disruption, making it suitable for pooled functional screens and population-based assays where clonal artifacts are undesirable. Researchers can employ this model to interrogate ASL-dependent metabolic pathways and assess consequences of ASL deficiency in a near-haploid genetic background.
HAP1 is a near-haploid human cell line originally derived from the chronic myeloid leukemia line KBM-7, characterized by a male karyotype containing approximately 25 chromosomes. Its haploid genome simplifies genetic manipulation and reduces functional redundancy, making it an ideal platform for functional genomics, chemical-genetic interaction studies, and high-throughput screening. The HAP1 background maintains robust proliferation in standard culture conditions and retains key signaling networks relevant to cancer biology. This host cell is widely adopted for CRISPR-based knockout screens and validation experiments due to the ease of generating complete genetic disruptions and the reduced likelihood of heterozygous confounding effects.
The ASL gene encodes argininosuccinate lyase, a urea cycle enzyme catalyzing the hydrolysis of argininosuccinate to arginine and fumarate. This reaction is essential for ammonia detoxification and arginine biosynthesis, linking it to nitric oxide, polyamine, and creatine production. ASL activity is regulated by glucagon, cAMP, glucocorticoids, and transcription factors HNF4A and C/EBP, while it interacts closely with ASS1 (which produces argininosuccinate) and ARG1 (which converts arginine to urea and ornithine). In the knockout cells, abrogation of ASL function leads to accumulation of argininosuccinate and depletion of arginine, disrupting downstream metabolic fates such as citrulline?Cnitric oxide cycle flux and fumarate generation.
In the HAP1 leukemia-derived background, ASL disruption creates a conditional arginine auxotrophy model, allowing investigation of metabolic dependencies in cancer. Since many tumor cells exhibit altered urea cycle enzyme expression, this polyclonal knockout pool enables studies on how loss of arginine self-sufficiency affects viability, proliferation, and stress responses in a minimal-chromosome context. Coupled with the haploid genome, it facilitates straightforward dissection of synthetic lethal interactions and metabolic vulnerabilities. The model also recapitulates molecular hallmarks of argininosuccinic aciduria, including metabolite imbalance and potential hyperammonemia-related cytotoxicity, providing a simplified human cellular system for preclinical research.
This product supports diverse applications such as modeling argininosuccinic aciduria, probing arginine auxotrophy in cancer, performing metabolic dependency screens, and drug discovery for urea cycle disorders. Typical assays include western blotting and RT-qPCR to confirm ASL disruption, LC-MS-based quantification of argininosuccinate and arginine, cell viability measurements in arginine-free media, and global metabolic profiling. Use of polyclonal populations enables robust statistical analyses and phenotypic screening without single-cell cloning artifacts. For further information regarding validation and use, please contact Ascent Research.
